Glenmark Pharmaceuticals (NSE:GLENMARK) Net Income From Continuing Operations : ₹-5,393 Mil (TTM As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Glenmark Pharmaceuticals Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Glenmark Pharmaceuticals's net income from continuing operations for the three months ended in Dec. 2023 was ₹-4,496 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was ₹-5,393 Mil.

Glenmark Pharmaceuticals Net Income From Continuing Operations Historical Data

The historical data trend for Glenmark Pharmaceuticals's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glenmark Pharmaceuticals Net Income From Continuing Operations Chart

Glenmark Pharmaceuticals Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Net Income From Continuing Operations

Get a 7-Day Free Trial

13,006.29

10,960.76

13,824.75

14,412.46

8,684.51

Glenmark Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Income From Continuing Operations	Get a 7-Day Free Trial															1,857.69	-825.32	1,731.28	-1,802.99	-4,495.80

Glenmark Pharmaceuticals Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-5,393 Mil.

Glenmark Pharmaceuticals (NSE:GLENMARK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Glenmark Pharmaceuticals Ltd (NSE:GLENMARK) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

532296:India

Address

Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri (East), Mumbai, IND, 400099

Website

https://www.glenmarkpharma.com

Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities.

Glenmark Pharmaceuticals (NSE:GLENMARK) Headlines

No Headlines